###begin article-title 0
Genetic Prediction of Future Type 2 Diabetes
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Competing Interests:</bold>
###xml 62 76 62 76 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PLoS Medicine.</italic>
Competing Interests: LG is a member of the editorial board of PLoS Medicine.
###end p 1
###begin p 2
###xml 0 21 0 21 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Author Contributions:</bold>
Author Contributions: VL extracted, genotyped, and analyzed the data, and drafted the report. PA and DA were responsible for the statistical analyses, MOM and MS for genotyping, and CS and TT for the phenotype data. LG designed the study and supervised all parts of the work including drafting the final report. All researchers took part in the revision of the report and approved the final version.
###end p 2
###begin article-title 3
Predicting the Development of Type 2 Diabetes
###end article-title 3
###begin title 4
Background
###end title 4
###begin p 5
Type 2 diabetes (T2D) is a multifactorial disease in which environmental triggers interact with genetic variants in the predisposition to the disease. A number of common variants have been associated with T2D but our knowledge of their ability to predict T2D prospectively is limited.
###end p 5
###begin title 6
Methods and Findings
###end title 6
###begin p 7
###xml 65 70 65 70 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 79 85 79 85 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 100 108 100 108 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">, KCNJ11</italic>
###xml 115 121 115 121 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">, UCP2</italic>
###xml 137 141 137 141 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 433 438 433 438 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 481 487 481 487 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 555 560 555 560 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 565 571 565 571 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 677 678 673 674 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 760 765 756 761 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 773 779 769 775 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 918 919 914 915 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 311 318 <span type="species:ncbi:9606">persons</span>
By using a Cox proportional hazard model, common variants in the PPARG (P12A), CAPN10 (SNP43 and 44), KCNJ11 (E23K), UCP2 (-866G>A), and IRS1 (G972R) genes were studied for their ability to predict T2D in 2,293 individuals participating in the Botnia study in Finland. After a median follow-up of 6 y, 132 (6%) persons developed T2D. The hazard ratio for risk of developing T2D was 1.7 (95% confidence interval [CI] 1.1-2.7) for the PPARG PP genotype, 1.5 (95% CI 1.0-2.2) for the CAPN10 SNP44 TT genotype, and 2.6 (95% CI 1.5-4.5) for the combination of PPARG and CAPN10 risk genotypes. In individuals with fasting plasma glucose >/= 5.6 mmol/l and body mass index >/= 30 kg/m2, the hazard ratio increased to 21.2 (95% CI 8.7-51.4) for the combination of the PPARG PP and CAPN10 SNP43/44 GG/TT genotypes as compared to those with the low-risk genotypes with normal fasting plasma glucose and body mass index < 30 kg/m2.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 65 70 65 70 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 75 81 75 81 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
We demonstrate in a large prospective study that variants in the PPARG and CAPN10 genes predict future T2D. Genetic testing might become a future approach to identify individuals at risk of developing T2D.
###end p 9
###begin p 10
###xml 130 136 <span type="species:ncbi:9606">person</span>
In a large prospective study, Lyssenko and colleagues show that variants in the PPARG and CAPN10 genes can help predict whether a person will develop Type 2 diabetes. 
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 151 152 151 152 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b01">1</xref>
###xml 269 270 269 270 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b02">2</xref>
###xml 412 413 412 413 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b03">3</xref>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
Type 2 diabetes (T2D) is a multifactorial disease in which environmental triggers interact with genetic variants in the predisposition to the disease [1]. T2D is characterized by impaired insulin secretion and insulin action in target tissues such as muscle and liver [2]. Many patients with a genetic predisposition to T2D also have a predisposition to weight gain, and obesity is a strong risk factor for T2D [3].
###end p 12
###begin p 13
###xml 64 65 64 65 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 66 67 66 67 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b07">7</xref>
###xml 295 296 295 296 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b08">8</xref>
###xml 303 308 303 308 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 401 402 401 402 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 403 404 403 404 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b09">9</xref>
###xml 405 407 405 407 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b11">11</xref>
###xml 685 693 685 693 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(CAPN10)</italic>
###xml 757 759 757 759 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b12">12</xref>
###xml 760 762 760 762 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b15">15</xref>
###xml 809 817 809 817 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(KCNJ11)</italic>
###xml 869 877 869 877 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(ABCC8),</italic>
###xml 1034 1040 1031 1037 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 1071 1073 1068 1070 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b16">16</xref>
###xml 1074 1076 1071 1073 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b18">18</xref>
###xml 1129 1135 1126 1132 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(IRS1)</italic>
###xml 1206 1208 1203 1205 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b19">19</xref>
###xml 1290 1291 1287 1288 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b08">8</xref>
###xml 1292 1294 1289 1291 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b20">20</xref>
###xml 1295 1297 1292 1294 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b21">21</xref>
###xml 1376 1378 1373 1375 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b22">22</xref>
###xml 1379 1381 1376 1378 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b23">23</xref>
Although several candidate genes have been associated with T2D [4-7], many findings have been difficult to replicate. The list of genes with support in extensive meta-analyses is relatively short, including genes encoding for PPARG, calpain 10, Kir 6.2, and insulin receptor substrate 1 (IRS1) [8]. The PPARG P12A polymorphism is associated with enhanced insulin sensitivity and protects against T2D [4,9-11]. Although the individual risk reduction for carriers of the rare A allele is only 15%, the population attributable risk of the common allele is about 25%. Two intronic single nucleotide polymorphisms (SNPs) (43 and 44) in the gene encoding for the cystein protease calpain 10 (CAPN10) confer increased susceptibility to insulin resistance and T2D [12-15]. The ATP-sensitive potassium channel Kir 6.2 (KCNJ11) forms together with the sulfonylurea receptor SUR1 (ABCC8), an octamer protein that regulates transmembrane potential and thereby glucose-stimulated insulin secretion in pancreatic beta-cells. A E23K polymorphism in KCNJ11 has been associated with T2D [16-18]. Carriers of a G972R polymorphism in the IRS1 gene (IRS1) have been shown to have reduced insulin content in pancreatic islets [19]. Although the meta-analyses suggested a role for the G972R polymorphism in T2D [8,20,21], two recent large case-control studies failed to replicate this association [22,23].
###end p 13
###begin p 14
###xml 113 119 113 119 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(UCP2)</italic>
###xml 217 221 217 221 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 290 292 290 292 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b24">24</xref>
###xml 293 295 293 295 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b27">27</xref>
###xml 355 357 355 357 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b28">28</xref>
###xml 519 521 519 521 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b29">29</xref>
In addition to the genes listed above, we considered it worthwhile to also include the uncoupling protein 2 gene (UCP2) in the analysis because some studies have associated a polymorphism in the promoter of the gene (UCP2 -866G>A) with increased risk of T2D and impaired insulin secretion [24-27], whereas other studies have reported reduced risk of T2D [28]. Increased expression of UCP2 in pancreatic islets is associated with increased uncoupling and thereby decreased ATP production required for insulin secretion [29].
###end p 14
###begin p 15
In this study, we tested variants in a number of candidate genes for T2D for their ability to predict diabetes in 2,293 individuals without diabetes participating in the Botnia prospective study in western Finland.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 6 18 <span type="species:ncbi:9606">Participants</span>
Study Participants
###end title 17
###begin p 18
###xml 100 102 100 102 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b30">30</xref>
###xml 103 105 103 105 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 187 189 187 189 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 349 351 349 351 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 1288 1291 1288 1291 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n =</italic>
###xml 1425 1427 1425 1427 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b32">32</xref>
###xml 414 426 <span type="species:ncbi:9606">participants</span>
###xml 513 525 <span type="species:ncbi:9606">Participants</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
###xml 593 605 <span type="species:ncbi:9606">participants</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
###xml 907 914 <span type="species:ncbi:9606">persons</span>
###xml 1066 1078 <span type="species:ncbi:9606">participants</span>
###xml 1434 1446 <span type="species:ncbi:9606">participants</span>
The Botnia study is a family-based study aiming to identify genes increasing susceptibility to T2D [30,31]. Details of the study cohort and sampling strategy have been presented earlier [31]. In brief, individuals with T2D from the area of five health-care centers in western Finland were invited to participate, together with their family members [31]. An oral glucose tolerance test (OGTT) was performed for all participants aged 18-70 y who had fasting plasma glucose concentration (FPG) lower than 11 mmol/l. Participants without diabetes, either family members of T2D patients or control participants (spouses without first or second degree family history of diabetes), between 18-70 y were offered prospective visits every 2-3 y. During the study period (which started in 1990 and was closed for this analysis in 2002), 1,869 relatives of T2D patients from 577 extended pedigrees (approximately three persons per pedigree) and 424 controls without family history of diabetes participated in at least OGTTs with a median follow-up of 6 y (range 2-12 y). Of the participants in both these groups, 1,569 had normal glucose tolerance and 724 had impaired fasting glucose and/or impaired glucose tolerance at baseline. Carriers of mutations causing maturity onset diabetes of the young (n = 20) were excluded from the present study. Glucose tolerance was defined according to the current World Health Organization criteria [32]. All participants gave informed consent, and the local ethics committee approved the study.
###end p 18
###begin title 19
Anthropometric Measurements and Assays
###end title 19
###begin p 20
###xml 120 122 120 122 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b30">30</xref>
###xml 123 125 123 125 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 615 617 615 617 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 649 651 649 651 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b33">33</xref>
###xml 792 806 777 791 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">30 min fasting</sub>
###xml 813 827 794 808 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">30 min fasting</sub>
###xml 1002 1004 983 985 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 4 16 <span type="species:ncbi:9606">participants</span>
###xml 233 245 <span type="species:ncbi:9606">participants</span>
The participants' weight, height, waist and hip circumference, and blood pressure were measured as previously reported [30,31]. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. All participants participated in a 75-g OGTT after a 12-h overnight fast. Fasting blood samples were drawn for the measurement of high density lipoprotein cholesterol, triglyceride, and free fatty acid concentrations, and at -10, 0, 30, 60, and 120 min for the measurement of plasma glucose and serum insulin. Insulin resistance was estimated as homeostasis model assessment index (HOMAIR) using a computer-based model [33] and beta-cell function as the ratio of incremental insulin to glucose responses during the first 30 min of the OGTT (DeltaI/DeltaG = DeltaI30 min fasting/DeltaG30 min fasting); this index is also called the insulinogenic index. The disposition index was used to adjust insulin secretion for the degree of insulin resistance (insulinogenic index/HOMAIR).
###end p 20
###begin title 21
Genotyping
###end title 21
###begin p 22
###xml 161 165 161 165 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 317 323 317 323 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 432 438 432 438 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 445 449 445 449 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 461 465 461 465 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 475 483 475 483 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="st001">Table S1</xref>
###xml 576 581 576 581 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 588 594 588 594 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 602 608 602 608 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 615 619 615 619 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 631 635 631 635 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 657 663 657 663 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 727 733 727 733 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 793 796 793 796 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 927 933 927 933 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
Genotyping of SNPs was performed with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method and agarose gel electrophoresis for IRS1 G972R, or using the Multiplex SNaPshot kit (Applied Biosystems, Stockholm, Sweden) for single base pair extension on ABI 3100 (Applied Biosystems) for CAPN10 SNP43 and 44, or with an allelic discrimination assay-by-design method on ABI 7900 (Applied Biosystems) for KCNJ11 E23K, IRS1 G972R, and UCP2 -866G>A (Table S1). By randomly regenotyping 10%-20% of the samples, we achieved concordance rates of 99% for PPARG P12A, CAPN10 SNP44, KCNJ11 E23K, IRS1 G972R, and UCP2 -866G>A, and 98% for CAPN10 SNP43. All genotypes were in Hardy-Weinberg equilibrium except CAPN10 SNP44, which showed a moderate deviation from equilibrium (p = 0.035). Genotyping errors are an unlikely explanation for this deviation from equilibrium, because in genotyping 1,880 samples of CAPN10 SNP44 using two different methods (allelic discrimination and single base extension) the concordance rate was 99%.
###end p 22
###begin title 23
Statistical Analyses
###end title 23
###begin p 24
###xml 62 63 60 61 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 593 595 591 593 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b34">34</xref>
Variables are presented as median (interquartile range). A chi2 test was used for comparison of group frequencies. Survival analysis was used to estimate the effect of genetic variants (risk and non-risk genotypes defined from previous studies) on the risk of developing T2D and shown by Kaplan-Meier survival curves as the distribution of age at onset (the proportion of individuals developing T2D at certain age). The risk of developing T2D was expressed as a hazard function (the negative slope divided by the survival curve) using an age-adjusted Cox proportional hazard regression model [34]. The hazard function is the (conditional) probability for the development of diabetes during a time interval divided by the length of that time interval, for an individual that is diabetes-free at the start of the time interval. The relative effect is presented as the ratio between the hazard functions (hazard ratio [HR]) of the two groups. HRs quantify the effect size of both discrete variables (carriers versus non-carriers) and continuous variables (used in the interaction analysis below where HR measures the effect of an increase in one unit of the continuous variable). All survival analyses were stratified for gender and adjusted for family history of diabetes and BMI (when appropriate). The information that an individual did not or did belong to a nuclear family with at least one other affected member was coded as zero or one, respectively, and used as a covariate in the Cox regression analyses. All survival analyses were performed with a robust variance estimate to adjust for within family dependence extended to the large pedigrees. In using a robust variance estimate we treated each pedigree (instead of each individual) as an independent entity for calculating the variance of the estimates.
###end p 24
###begin p 25
###xml 82 88 82 88 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG,</italic>
###xml 104 110 104 110 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 133 139 133 139 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 166 173 166 173 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11,</italic>
###xml 193 198 193 198 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1,</italic>
###xml 214 218 214 218 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 254 260 254 260 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 320 322 320 322 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b13">13</xref>
###xml 323 325 323 325 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b14">14</xref>
###xml 392 394 392 394 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b15">15</xref>
###xml 485 491 485 491 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 637 643 637 643 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
Expected risk genotypes were defined according to earlier reports (PP genotype of PPARG, GG genotype of CAPN10 SNP43, TT genotype of CAPN10 SNP44, EK/KK genotypes of KCNJ11, GR/RR genotypes of IRS1, GG genotype of UCP2). However, the risk TT genotype of CAPN10 SNP44 was in opposite direction compared to other studies [13,14] and selected based upon a previous report from the Botnia study [15] showing that the combination of the TT genotype of SNP44 and the GG genotype of SNP43 in CAPN10 was significantly more frequent in patients with T2D than in control individuals. Therefore, in the present study we refer to the TT genotype of CAPN10 SNP44 as an at-risk genotype. Individuals with missing data were excluded from the analyses.
###end p 25
###begin p 26
###xml 52 55 52 55 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(P)</italic>
###xml 129 131 129 131 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 146 149 146 149 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(G)</italic>
###xml 270 271 270 271 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 276 277 276 277 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 278 279 278 279 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 288 289 285 286 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 289 290 286 287 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 297 298 291 292 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 298 299 292 293 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 306 307 297 298 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 307 308 298 299 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 309 310 300 301 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 324 325 315 316 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 355 356 346 347 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 357 358 348 349 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 402 403 390 391 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 412 413 397 398 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 455 456 437 438 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 516 517 495 496 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 679 680 650 651 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 729 731 700 702 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">(P</italic>
###xml 734 736 705 707 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x)</italic>
###xml 753 754 721 722 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 761 762 726 727 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 764 765 729 730 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 814 815 776 777 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 816 817 778 779 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1294 1295 1256 1257 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Analyses of interaction between effect of phenotype (P) defined as insulin secretion (disposition index) and insulin action (HOMAIR) and genotype (G) (1 = risk and 0 = non-risk) on age at onset of T2D were performed using the following Cox proportional hazards model: h(t) = h0(t)exp(beta1P + beta2G + beta3P*G), in which h(t) is the hazard function and h0(t) is the baseline hazard function, with beta1 and beta2 measuring the univariate effects and beta3 measuring the interaction. If there is an interaction (beta3 not equal 0), the HR for carriers and non-carriers of the risk genotype will not be the same. Thus, in different genotype carriers the HR of T2D associated with x units increase/decrease in the phenotypic value (P + x) is HR = exp(beta1 + beta3)*x for the risk genotype carriers and HR = exp(beta1*x) for the non-risk genotype carriers. A logistic regression analysis was applied to explore the relationship between FPG and BMI, with genetic factor (defined as 1 = risk and 0 = non-risk) as dependent variable and FPG, BMI, and an interaction term as covariates. All statistical analyses were performed using Number Crunching Statistical Systems version 2004 (NCSS, Kaysville, Utah, United States), R (, and Stata (StataCorp, College Station, Texas, United States). Two-sided p-values of less than 0.05 were considered statistically significant.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 80 87 80 87 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t001">Table 1</xref>
###xml 179 180 175 176 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 236 237 230 231 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 16 23 <span type="species:ncbi:9606">persons</span>
###xml 31 34 <span type="species:ncbi:9606">men</span>
###xml 45 50 <span type="species:ncbi:9606">women</span>
###xml 252 259 <span type="species:ncbi:9606">persons</span>
###xml 283 286 <span type="species:ncbi:9606">men</span>
###xml 294 299 <span type="species:ncbi:9606">women</span>
In total, 2,293 persons (1,051 men and 1,242 women) were included in the study (Table 1). Of them, 1,078 (47%) had non-normal FPG (>/= 5.6 mmol/l), 280 (12.3%) had BMI >/= 30 kg/m2, and 160 (7%) had both elevated FPG and BMI >/= 30 kg/m2. Of the 2,293 persons included, 132 (6%) (67 men and 65 women; 40 with normal and 92 with abnormal glucose tolerance) developed diabetes during the follow-up period of 6 y (converters).
###end p 28
###begin title 29
###xml 0 5 0 5 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
PPARG
###end title 29
###begin p 30
###xml 43 48 43 48 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 124 125 124 125 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 186 193 186 193 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t002">Table 2</xref>
###xml 338 341 338 341 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 350 358 350 358 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g001">Figure 1</xref>
###xml 360 367 360 367 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 489 490 485 486 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 533 535 529 531 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 564 569 560 565 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 835 838 831 834 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 847 855 843 851 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g002">Figure 2</xref>
###xml 932 935 928 931 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 971 978 967 974 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 985 990 981 986 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1126 1131 1122 1127 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1189 1192 1185 1188 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 1359 1364 1355 1360 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1391 1393 1387 1389 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 1395 1398 1391 1394 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 1459 1461 1455 1457 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 1566 1574 1562 1570 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g003">Figure 3</xref>
###xml 142 154 <span type="species:ncbi:9606">participants</span>
The allele and genotype frequencies of the PPARG P12A polymorphism were similar to those previously reported in Caucasians [4], with 73.3% of participants carrying the risk PP genotype (Table 2). Of all individuals who developed T2D, 109 (82.6%) had the PP genotype, which also significantly increased the risk of subsequent T2D (HR 1.7, p = 0.016) (Figure 1; Table 3). Because we have previously shown that a family history of diabetes, non-normal FPG (>/= 5.6 mmol/l), and BMI >/= 30kg/m2 identify individuals at high risk of T2D [31], we now tested whether the PPARG risk genotype could replace family history in this prediction. In fact, the incidence of T2D was increased in carriers of the PP genotype with elevated FPG and high BMI as compared with the PA/AA genotype carriers without any other risk factors (22.9% versus 1.5%, p < 0.001) (Figure 2). This corresponded to a HR of 13.5 (95% confidence interval [CI] 4.5-40.7, p < 0.001) estimated by the Cox model (Table 3). The PPARG genotype also influenced the relationship between BMI and FPG; there was a stronger correlation between BMI and FPG in carriers of the PPARG PP as compared to the PA/AA genotypes (0.23 versus 0.15, p = 0.041), suggesting a steeper increase in FPG for any increase in BMI in carriers of the risk genotype. Furthermore, we observed a significant interaction between the PPARG P12A polymorphism and HOMAIR (p = 0.004), indicating that with increasing insulin resistance [31] carriers of the PP genotype had a greater risk of developing T2D than carriers of the PA/AA genotypes (Figure 3).
###end p 30
###begin p 31
###xml 87 88 87 88 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 98 101 98 101 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 551 554 551 554 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 567 575 567 575 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g001">Figure 1</xref>
###xml 577 584 577 584 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 847 850 847 850 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 863 871 863 871 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g002">Figure 2</xref>
###xml 956 959 956 959 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 968 975 968 975 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 1061 1063 1061 1063 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 1132 1134 1132 1134 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 1136 1139 1136 1139 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 1150 1153 1150 1153 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 1245 1247 1245 1247 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 131 143 <span type="species:ncbi:9606">participants</span>
The G allele of SNP43 and the C allele of SNP44 were in strong linkage disequilibrium (D' = 0.99, p < 0.001). Fifty percent of the participants had the risk genotype (GG) of SNP43 and 62.1% had the risk genotype (TT) of SNP44. A total of 534 (24%) individuals carried both the GG (SNP43) and the TT (SNP44) genotypes. Seventy (54.3%) of the converters had the GG (SNP43) genotype, while 91 (70.0%) had the TT (SNP44) genotype. While SNP43 had no effect on its own, the SNP44 TT genotype was associated with a moderately increased risk of T2D (HR 1.5, p = 0.035) (see Figure 1; Table 3). The incidence of T2D was highest in individuals carrying both SNP43 (GG) and SNP44 (TT) genotypes and other risk factors, particularly those with high BMI, as compared with individuals with low risk genotypes without any other risk factors (36.7% versus 3.0%, p < 0.001) (see Figure 2). In the age-adjusted Cox analysis, the corresponding HR was 13.2 (95% CI 6.0-28.7, p < 0.001) (Table 3). Also, there was a significant interaction between the GG genotype of SNP43 and HOMAIR, and between the combination of both risk genotypes (GG/TT) and HOMAIR (p = 0.037 and p = 0.028, respectively), showing that the risk conferred by worsening of insulin sensitivity [31] increased more in carriers of these genotypes than in carriers of the low risk genotypes.
###end p 31
###begin title 32
###xml 0 4 0 4 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
UCP2
###end title 32
###begin p 33
###xml 88 92 88 92 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 188 191 188 191 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 204 212 204 212 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g001">Figure 1</xref>
###xml 214 221 214 221 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 432 435 432 435 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 445 452 445 452 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t004">Table 4</xref>
###xml 579 582 579 582 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 593 594 591 592 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 636 639 634 637 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
Fifty-eight (44.3%) of the converters were homozygous for the risk genotype (GG) of the UCP2 -866G>A variant. The GG genotype was associated with a modestly increased risk of T2D (HR 1.4, p = 0.049) (see Figure 1; Table 3). This risk was not influenced by BMI and FPG at baseline. However, the GG genotype was also associated with increased risk of developing T2D in patients with earlier onset of diabetes (HR 2.0, 95% CI 1.2-3.3, p = 0.0057) (Table 4). Furthermore, the GG genotype was also more frequent among patients with earlier than late onset of T2D (60.3% versus 39.7%, p = 0.042; chi2 test and odds ratio 2.5, 95% CI 1.2-5.3, p = 0.016; logistic regression analyses adjusted for gender, BMI, and family history of diabetes). None of the other tested genotypes predicted significantly earlier onset of T2D.
###end p 33
###begin title 34
###xml 0 4 0 4 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
IRS1
###end title 34
###begin p 35
###xml 67 71 67 71 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 277 278 275 276 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 304 307 302 305 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 320 327 318 325 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 227 239 <span type="species:ncbi:9606">participants</span>
Twenty-three (17.6%) converters carried the RR/RG genotypes of the IRS1 G972R polymorphism. Whereas the R allele had no independent effect on T2D risk, it increased the risk of T2D in a dominant fashion (RR or RG versus GG) in participants with elevated FPG and BMI >/= 30 kg/m2 to 9.3 (95% CI 3.6-23.9, p < 0.001) (see Table 3).
###end p 35
###begin title 36
###xml 0 6 0 6 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
KCNJ11
###end title 36
###begin p 37
###xml 66 72 66 72 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 295 297 295 297 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b16">16</xref>
###xml 298 300 298 300 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b18">18</xref>
###xml 351 357 351 357 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 403 406 403 406 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 488 490 488 490 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
Ninety-six converters (73.8%) had the risk EK/KK genotypes of the KCNJ11 E23K polymorphism, but these genotypes did not increase risk of future T2D, neither alone nor in combination with elevated FPG or high BMI. In line with previous findings of an effect of this variant on insulin secretion [16-18], there was a significant interaction between the KCNJ11 E23K polymorphism and the disposition index (p < 0.001), suggesting that the risk of T2D associated with a low disposition index [31] is increased by the EK/KK genotypes.
###end p 37
###begin title 38
Combined Genetic Effects
###end title 38
###begin p 39
###xml 67 72 67 72 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 82 88 82 88 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 159 164 159 164 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 171 177 171 177 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 188 192 188 192 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 222 227 222 227 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 235 241 235 241 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 391 398 391 398 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 510 516 510 516 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 548 555 548 555 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 561 569 561 569 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g001">Figure 1</xref>
###xml 698 705 698 705 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10,</italic>
###xml 729 734 729 734 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 872 875 872 875 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 888 896 888 896 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020345-g002">Figure 2</xref>
###xml 935 938 935 938 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 947 954 947 954 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
###xml 1197 1200 1197 1200 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p =</italic>
###xml 632 644 <span type="species:ncbi:9606">participants</span>
In total, 1,028 (45.9%) individuals carried risk genotypes in both PPARG (PP) and CAPN10 SNP44 (TT), whereas 397 (18.2%) individuals had three risk genotypes: PPARG (PP), CAPN10 (TT), and UCP2 (GG). The effect of both the PPARG PP and CAPN10 SNP44 TT genotypes on the risk of subsequent T2D when present in the same individual was greater (HR 2.6, 95% CI 1.5-4.5) than the individual risks (Table 3). The effect was even stronger when the combination of at-risk GG and TT genotypes of both SNP43 and 44 of the CAPN10 gene (HR 3.3, 95% CI 1.7-6.8) (Table 3; see Figure 1) was included in the analysis. Again, the incidence of T2D in participants with the combination of SNP43 (GG) and SNP44 (TT) in CAPN10, the PP genotype in the PPARG gene, elevated FPG, and high BMI was markedly higher than in those with low risk genotypes and no other risk factors (44.7% versus 3.0%, p < 0.001) (see Figure 2), with a HR of 21.2 (95% CI 8.7-51.4, p < 0.001) (Table 3). Also, these combinations influenced the correlation between BMI and FPG, yielding a steeper increase in FPG for any increase in BMI in carriers of the risk genotype combinations than in carriers of the non-risk genotypes (0.28 versus 0.19, p = 0.041).
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 62 67 62 67 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 72 78 72 78 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 405 406 405 406 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b06">6</xref>
###xml 725 730 725 730 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 744 750 744 750 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 753 754 753 754 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 755 757 755 757 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b15">15</xref>
The key finding of the present study was that variants in the PPARG and CAPN10 genes increased the future risk for T2D, particularly in individuals with other risk factors. A question often raised about genetic association studies of polygenic diseases is whether the information can be used to predict the disease, since the risk conferred by the variant is usually rather modest (odds ratio < 1.2-1.3) [6]. In T2D association studies, cases are usually ascertained through diabetes clinics and thereby possibly enriched by carriers of more severe genetic variants. It was therefore encouraging to see that polymorphisms in some genes previously shown to be associated with T2D in case-control studies (particularly P12A in PPARG and SNP44 in CAPN10) [4,15] could predict T2D in high risk individuals from families with T2D.
###end p 41
###begin p 42
###xml 25 26 20 21 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">s</sub>
###xml 153 154 146 147 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 235 237 226 228 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b31">31</xref>
###xml 278 283 269 274 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 288 294 279 285 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
The relative risk (lambdas) of developing T2D for members of the Botnia families is about three. However, this risk is greatest in obese (BMI >/= 30 kg/m2) individuals with FPG above normal (>/=5.6 mmol/l) and a family history of T2D [31]. Replacing the family history with the PPARG and CAPN10 variants, and particularly with their combination, gave almost the same strong prediction of subsequent T2D. These genotypes also influenced the relationship between BMI and FPG, i.e., in carriers of the risk genotypes there was a steeper increase in FPG for any given increase in BMI.
###end p 42
###begin p 43
###xml 166 167 166 167 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b09">9</xref>
###xml 168 170 168 170 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b17">17</xref>
###xml 198 200 198 200 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b11">11</xref>
###xml 475 476 475 476 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b09">9</xref>
###xml 477 479 477 479 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b17">17</xref>
###xml 498 500 498 500 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b11">11</xref>
Several papers have examined the effect of single gene variants on the risk of conversion to T2D in interventional trials like the Finnish Diabetes Prevention Study [9,17] and the STOP-NIDDM trial [11]. However, it is important to know the effect of these genetic variants on risk of future T2D in an observational study before conclusions can be drawn on their putative additive or synergistic effects, together with the effects of specific factors such life style changes [9,17] or acarbose use [11]. Many of these studies have provided conflicting results in different subgroups; this is a natural corollary of their design, which breaks the initial cohorts down in relatively small subgroups with limited power. Although the present study also has limited power, it is to our knowledge the largest of its kind, and it also provides information on key T2D variants in the same paper.
###end p 43
###begin title 44
###xml 0 5 0 5 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
PPARG
###end title 44
###begin p 45
###xml 25 30 25 30 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 165 168 165 168 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 176 177 176 177 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 178 179 178 179 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b08">8</xref>
###xml 267 272 267 272 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 400 402 400 402 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b35">35</xref>
###xml 454 456 454 456 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b36">36</xref>
###xml 553 555 553 555 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 698 700 698 700 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b10">10</xref>
###xml 852 854 852 854 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b11">11</xref>
###xml 1084 1085 1084 1085 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b09">9</xref>
###xml 1392 1394 1392 1394 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b37">37</xref>
###xml 1776 1778 1776 1778 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b38">38</xref>
###xml 1873 1878 1873 1878 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 810 815 <span type="species:ncbi:9606">women</span>
The P12A polymorphism in PPARG is to date the best replicated genetic variant for T2D, with a cumulative odds ratio from published studies of about 1.25 and overall p < 0.001 [4,8]. The P12A variant is located in an extra exon B in the 5'-end of the adipose-specific PPARG2 isoform and shows reduced transcription of target genes. The A allele has been associated with increased insulin sensitivity [35], particularly, enhanced suppression of lipolysis [36]. In support of this, there was a significant interaction between the P12A polymorphism and HOMAIR (which measures insulin resistance). The Nurse's Health Study also reported reduced risk for developing diabetes in carriers of the A allele [10]. Most recently, the STOP-NIDDM trial also reported that the PP genotype predicted conversion to diabetes in women in the acarbose intervention group [11]. These combined data, however, contrast with findings in the Finnish Diabetes Prevention Study, which reported an increased risk of developing diabetes in carriers of the A allele compared to individuals with the P12P genotype [9]. This effect was restricted to the control group, whereas the few A12A carriers in the intervention group lost more weight than the P12P carriers. As enhanced insulin sensitivity is a risk factor for weight gain, the A allele has also been associated with more rapid weight regain after weight reduction [37]. It is therefore possible that the protective effect of the A allele is attenuated in very obese individuals. Differences in BMI cannot fully explain the different results, since the risk conferred by the P12P genotype was maintained after adjusting for BMI in the present study. The effect of the P12A variant on BMI and lipolysis is also dependent upon intake of saturated fat [38]. Taken together, the data suggest a complex interaction between the P12A polymorphism in the PPARG gene and diet, body weight, and insulin sensitivity in predicting risk of future T2D.
###end p 45
###begin p 46
###xml 115 116 115 116 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b04">4</xref>
###xml 208 210 208 210 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b10">10</xref>
###xml 211 213 211 213 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b11">11</xref>
###xml 935 940 935 940 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1484 1492 <span type="species:ncbi:9606">patients</span>
Notably, the HR in the present prospective study was higher than the odds ratios in previous case-control studies [4]. The same also applies to the odds ratios obtained in the intervention studies discussed [10,11]. Although there could be several possible explanations for this discrepancy, a likely explanation is the accuracy by which the cases (converters) and controls (non-converters) were defined in the prospective study as compared with a case-control association study. In the prospective study all individuals underwent repeated OGTTs to define glucose tolerance status, while in case-control studies the definition of normal glucose tolerance is often based upon one OGTT. Therefore, we assume that we have a certain proportion of controls misclassified. We simulated (1,000 times) this situation by introducing 5%, 10%, and 20% misclassification of non-converters regarding the HR of 1.72 for the P12A polymorphism in the PPARG gene to predict future diabetes. A 5% misclassification would result in a decrease in HR to 1.31 (minimum 0.85; maximum 1.97), 10% to 1.18 (minimum 0.84; maximum 1.68), and 20% to 1.08 (minimum 0.82; maximum 1.38). Of course, there also could be other factors contributing, such as change in diabetes prevalence (which almost doubled) between the time when the cases in the case-control study and the converters in the prospective study were diagnosed. Finally, our study was carried out in a high risk population of first degree relatives of patients with T2D.
###end p 46
###begin title 47
###xml 0 6 0 6 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
CAPN10
###end title 47
###begin p 48
###xml 40 46 40 46 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 179 181 179 181 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b12">12</xref>
###xml 471 473 471 473 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b13">13</xref>
###xml 474 476 474 476 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b14">14</xref>
###xml 519 521 519 521 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b13">13</xref>
###xml 522 524 522 524 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b14">14</xref>
###xml 620 622 620 622 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b15">15</xref>
###xml 749 751 749 751 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b15">15</xref>
###xml 806 812 806 812 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 899 901 899 901 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b39">39</xref>
###xml 943 945 943 945 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 954 960 954 960 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 1056 1062 1056 1062 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPPARG</italic>
###xml 1067 1073 1067 1073 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
The discovery that intronic SNPs in the CAPN10 gene explained the linkage to Chromosome 2q in Mexican-Americans represented the first successful positional cloning of a T2D gene [12]. It also raised a number of questions, e.g., how could these intronic SNPs in a gene encoding a cystein protease confer increased risk of T2D? Several recent meta-analyses have demonstrated a consistent but modest risk of SNP43 and 44 (odds ratio 1.15-1.20) for the association with T2D [13,14]. In opposite direction to other studies [13,14], in the Botnia study the TT genotype of SNP44 has been associated with increased risk of T2D [15]. However, a stronger association was seen for the combination of both the GG genotype of SNP43 and the TT genotype of SNP44 [15]. Carriers of the GG genotype of SNP43 have decreased CAPN10 mRNA levels in skeletal muscle, which correlates with more severe insulin resistance [39]. Our data of an interaction between HOMAIR and the CAPN10 SNP43 supports this notion. The question arises whether the combined effect of variants in the PPPARG and CAPN10 genes on risk for future T2D can be solely explained by the variants' effect on insulin sensitivity. A combined effect of the two genes on both insulin secretion and action would be more plausible. However, the knowledge of molecular mechanisms by which calpain 10 would increase susceptibility to T2D is limited.
###end p 48
###begin title 49
###xml 0 4 0 4 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
UCP2
###end title 49
###begin p 50
###xml 118 120 118 120 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b40">40</xref>
###xml 151 155 151 155 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 242 246 242 246 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 329 331 329 331 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b41">41</xref>
###xml 379 383 379 383 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 399 404 <span type="species:ncbi:9606">human</span>
Impaired insulin secretion has been shown to predominate over insulin resistance in individuals with early onset T2D [40]. In line with this view, the UCP2 variant was a strong predictor of T2D with earlier onset. The promoter variant in the UCP2 gene has been associated with increased expression of the gene in adipose tissue [41]. If this variant is associated with increased UCP2 mRNA levels in human pancreatic beta-cells (which is not known), this could result in increased uncoupling and, in turn, in decreased formation of ATP and impaired insulin secretion.
###end p 50
###begin title 51
###xml 0 6 0 6 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
KCNJ11
###end title 51
###begin p 52
###xml 24 30 24 30 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 76 78 76 78 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b16">16</xref>
###xml 79 81 79 81 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b18">18</xref>
###xml 134 136 134 136 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b42">42</xref>
###xml 307 309 307 309 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020345-b43">43</xref>
###xml 316 322 316 322 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 531 537 531 537 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 399 411 <span type="species:ncbi:9606">participants</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
Genetic variants in the KCNJ11 gene have not only been associated with T2D [16,18], but also with a severe form of neonatal diabetes [42]. Whereas these neonatal mutations result in a 10-fold activation of the ATP-dependent potassium channel, the E23K variant results in only a 2-fold increase in activity [43]. The KCNJ11 E23K variant did not significantly increase the risk for T2D in our study's participants. We have no explanation for this finding other than lack of power (the study had only 52% power to detect an effect of KCNJ11 E23K on risk of developing T2D) or the presence of other unidentified risk factors in the patients with manifest T2D. We did, however, observe an interaction between the EK and/or KK genotypes and impaired beta-cell function, supporting a role in insulin secretion.
###end p 52
###begin title 53
Conclusion
###end title 53
###begin p 54
In conclusion, we show in a large observational prospective study that genetic variants in candidate genes can predict future T2D, particularly in association with conventional risk factors such as obesity and abnormal glucose tolerance. With accumulating data from prospective studies, it should be possible to define whether there will be a future role for these variants in genetic prediction of T2D and whether these variants will influence response to prevention or treatment.
###end p 54
###begin p 55
Although this study is, to our knowledge, the largest of its kind thus far, it still has limited power to detect an effect of low-frequency alleles. It is therefore obvious that larger studies with longer follow-up are needed to replicate the findings. One such resource will be the Malmo Diabetes Prevention cohort, in which 22,000 individuals have been followed for more than 20 y. They are presently being restudied to obtain DNA and information on whether they have developed diabetes or not. While waiting for these results, it will be important to create consortia to merge data from available prospective studies.
###end p 55
###begin title 56
Supporting Information
###end title 56
###begin title 57
Primers and Probes Used in the Study
###end title 57
###begin p 58
(92 KB PDF).
###end p 58
###begin p 59
Click here for additional data file.
###end p 59
###begin title 60
The Number of Individuals Who Developed T2D Carrying Different Risk Factors
###end title 60
###begin p 61
(93 KB PDF).
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin title 63
Accession Numbers
###end title 63
###begin p 64
###xml 87 93 87 93 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 113 119 113 119 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 139 143 139 143 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IRS1</italic>
###xml 163 169 163 169 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 185 190 185 190 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 213 217 213 217 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
The NCBI Entrez () accession numbers for the polymorphisms discussed in this paper are CAPN10 SNP43 (rs3792267), CAPN10 SNP44 (rs2975760), IRS1 G972R (rs1801278), KCNJ11 E23K (rs5219), PPARG P12A (rs1801282), and UCP2 -866G>A (rs659366).
###end p 64
###begin title 65
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Summary
###end title 65
###begin title 66
Background
###end title 66
###begin p 67
###xml 546 552 <span type="species:ncbi:9606">person</span>
Type 2 diabetes, also known as adult onset or non-insulin-dependent diabetes, is increasing in frequency around the world. Many different factors work together to make someone more likely to develop diabetes, including factors in their environment-for example, the food they eat-and in their family background-the genes they inherited from their parents. Many studies have been done looking at which genes are associated with diabetes, but few have tried to see whether it is possible to predict who will get diabetes in future from looking at a person's genes before any symptoms develop.
###end p 67
###begin title 68
Why Was This Study Done?
###end title 68
###begin p 69
###xml 116 122 <span type="species:ncbi:9606">people</span>
These authors wanted to look at changes in five genes previously shown to be associated with diabetes in a group of people who were to be followed prospectively-that is, from before they developed diabetes-and see if it was possible to predict who would get diabetes.
###end p 69
###begin title 70
What Did the Researchers Do and Find?
###end title 70
###begin p 71
###xml 333 338 333 338 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 400 406 400 406 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 19 25 <span type="species:ncbi:9606">people</span>
###xml 75 81 <span type="species:ncbi:9606">people</span>
###xml 166 172 <span type="species:ncbi:9606">people</span>
###xml 479 485 <span type="species:ncbi:9606">people</span>
###xml 586 598 <span type="species:ncbi:9606">participants</span>
They studied 2,293 people in Finland who were family members or spouses of people with type 2 diabetes, but who themselves did not have diabetes. They followed these people for up to 12 years, starting in 1990. In total, 132 of these individuals (6%) developed diabetes during this time. They found that changes in two of the genes, PPARG (which is involved in how the body regulates fat tissue) and CAPN10 (which is involved in modifying certain proteins), were associated with people having a higher chance of getting type 2 diabetes. This chance was increased substantially when the participants already had slightly raised blood glucose, and a high body mass index.
###end p 71
###begin title 72
What Do These Findings Mean?
###end title 72
###begin p 73
###xml 8 14 <span type="species:ncbi:9606">people</span>
###xml 80 86 <span type="species:ncbi:9606">person</span>
###xml 207 213 <span type="species:ncbi:9606">people</span>
In some people, it does seem possible to use certain genes to predict whether a person will develop type 2 diabetes. However, environmental factors are also very important, and any risk is much increased in people who are already overweight.
###end p 73
###begin title 74
Where Can I Get More Information Online?
###end title 74
###begin p 75
MedlinePlus has many links to pages of information on diabetes:
###end p 75
###begin p 76

###end p 76
###begin p 77
The Finnish Diabetes Association has information on diabetes in general and more specifically for Finland:
###end p 77
###begin p 78

###end p 78
###begin p 79
###xml 519 527 <span type="species:ncbi:9606">patients</span>
This work was supported by grants from the Sigrid Juselius Foundation, European Community (Genomic Integrated Force for Type 2 Diabetes, grant QLG2-Ct-1999-0546), Folkhalsan Research Foundation, the Swedish Research Council, Academy of Finland, the Lundberg Foundation, the Novo Nordic Foundation, the European Federation for the Study of Diabetes (Sankyo Pharma), the Diabetes Research Foundation, the Albert Pahlssons Foundation, Crafoord Foundation, and the Anna-Lisa and Sven-Eric Lundgren Foundation. We thank the patients for their participation and the Botnia research team, as well as Malin Svensson and Barbro Gustavsson for excellent technical assistance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 79
###begin p 80
###xml 0 22 0 22 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">The Botnia Study Group</bold>
The Botnia Study Group
###end p 80
###begin p 81
Investigator from Vasa, Finland: Mikael Nissen.
###end p 81
###begin p 82
Investigators from Jakobstads Health Center, Jakobstads Hospital, and Folkhalsan Ostanlid, Jakobstad, Finland: Bo Isomaa, Leena Sarelin, and Carola Svenfelt.
###end p 82
###begin p 83
Investigators from Korsholms Health Center, Korsholm, Finland: Ulla-Britt Bjork, Nils Holmstrom, and Jessica Strand.
###end p 83
###begin p 84
Investigators from Malax Health Center, Malax, Finland: Lisbeth Akerman and Inga-Britt Stenback.
###end p 84
###begin p 85
Investigators from Narpes Health Center, Narpes, Finland: Bjorn Forsen, Monika Gullstrom, Maja Haggblom, and Susann Soderback.
###end p 85
###begin p 86
Investigators from Vasa Health Center, Vasa, Finland: Kaj Lahti, Marianne Nyman, and Sonja Paulaharju.
###end p 86
###begin p 87
Investigators from Department of Medicine, Helsinki University Central Hospital; Folkhalsan Research Center, Department of Genetics, and Research Program for Molecular Medicine, University of Helsinki, Helsinki, Finland: Seija Heikkinen, Paula Kokko, Merja Lahtinen, Mikko Lehtovirta, and Virve Lundgren.
###end p 87
###begin p 88
Investigators from Department of Medicine, Helsinki University Central Hospital; Research Program for Cardiovascular Diseases, University of Helsinki, Helsinki, Finland: Hannele Hilden and Marja-Riitta Taskinen.
###end p 88
###begin p 89
Investigators from Department of Clinical Sciences, Diabetes, and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden: Esa Laurila and Margareta Svensson.
###end p 89
###begin title 90
References
###end title 90
###begin article-title 91
Global and societal implications of the diabetes epidemic
###end article-title 91
###begin article-title 92
Alterations of glucose metabolism in type 2 diabetes mellitus. An overview
###end article-title 92
###begin article-title 93
###xml 84 87 <span type="species:ncbi:9606">men</span>
Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men
###end article-title 93
###begin article-title 94
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
###end article-title 94
###begin article-title 95
Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action
###end article-title 95
###begin article-title 96
The inherited basis of diabetes mellitus: Implications for the genetic analysis of complex traits
###end article-title 96
###begin article-title 97
Common polymorphisms in the genes regulating the early insulin signalling pathway: Effects on weight change and the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study
###end article-title 97
###begin article-title 98
Candidate genes for type 2 diabetes
###end article-title 98
###begin article-title 99
Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study
###end article-title 99
###begin article-title 100
Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes
###end article-title 100
###begin article-title 101
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial
###end article-title 101
###begin article-title 102
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
###end article-title 102
###begin article-title 103
Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility
###end article-title 103
###begin article-title 104
Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies
###end article-title 104
###begin article-title 105
Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels
###end article-title 105
###begin article-title 106
Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes
###end article-title 106
###begin article-title 107
Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study
###end article-title 107
###begin article-title 108
Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region
###end article-title 108
###begin article-title 109
###xml 51 56 <span type="species:ncbi:9606">human</span>
Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism
###end article-title 109
###begin article-title 110
Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: A meta-analysis of 27 studies
###end article-title 110
###begin article-title 111
Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset
###end article-title 111
###begin article-title 112
###xml 29 35 <span type="species:ncbi:9606">people</span>
Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes
###end article-title 112
###begin article-title 113
The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with type 2 diabetes mellitus in two population-based studies
###end article-title 113
###begin article-title 114
Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion
###end article-title 114
###begin article-title 115
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients
###end article-title 115
###begin article-title 116
###xml 44 49 <span type="species:ncbi:9606">human</span>
The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes
###end article-title 116
###begin article-title 117
The common -866G/A polymorphism in the promoter region of the UCP2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy
###end article-title 117
###begin article-title 118
###xml 126 132 <span type="species:ncbi:9606">humans</span>
A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans
###end article-title 118
###begin article-title 119
Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: Mechanism of action
###end article-title 119
###begin article-title 120
Metabolic consequences of a family history of NIDDM (the Botnia study): Evidence for sex-specific parental effects
###end article-title 120
###begin article-title 121
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes
###end article-title 121
###begin article-title 122
Correct homeostasis model assessment (HOMA) evaluation uses the computer program
###end article-title 122
###begin article-title 123
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
###end article-title 123
###begin article-title 124
Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2?
###end article-title 124
###begin article-title 125
Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain
###end article-title 125
###begin article-title 126
Evidence for gene-nutrient interaction at the PPARgamma locus
###end article-title 126
###begin article-title 127
A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance
###end article-title 127
###begin article-title 128
Type II diabetes of early onset: A distinct clinical and genetic syndrome?
###end article-title 128
###begin article-title 129
###xml 106 112 <span type="species:ncbi:9606">humans</span>
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans
###end article-title 129
###begin article-title 130
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes
###end article-title 130
###begin article-title 131
Diabetes and insulin secretion: Whither KATP?
###end article-title 131
###begin title 132
Abbreviations
###end title 132
###begin p 133
body mass index
###end p 133
###begin p 134
confidence interval
###end p 134
###begin p 135
fasting plasma glucose concentration
###end p 135
###begin p 136
homeostasis model assessment index
###end p 136
###begin p 137
hazard ratio
###end p 137
###begin p 138
oral glucose tolerance test
###end p 138
###begin p 139
type 2 diabetes
###end p 139
###begin p 140
single nucleotide polymorphism
###end p 140
###begin title 141
Figures and Tables
###end title 141
###begin title 142
Unadjusted Kaplan-Meier Diabetes-Free Survival Probability Curves
###end title 142
###begin p 143
###xml 33 38 33 38 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 63 69 63 69 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 95 99 95 99 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 151 156 151 156 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 161 167 161 167 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 202 204 202 204 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">y-</italic>
###xml 259 260 259 260 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 528 535 528 535 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020345-t003">Table 3</xref>
Curves for different carriers of PPARG P12A (PP versus PA/AA), CAPN10 SNP44 (TT versus TC/CC), UCP2 -866 G/A (GG versus GA/AA), and the combination of PPARG and CAPN10 SNP43/44 (PP/GG/TT versus other). y-Axis shows probability of diabetes-free survival time. x-Axis shows follow-up time in years. The HR of developing T2D in different genotype carriers obtained from Cox proportional hazards regression stratified on sex and adjusted for age, BMI, and family history of diabetes with robust variance estimate is shown (see also Table 3).
###end p 143
###begin title 144
###xml 37 42 37 42 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 86 92 86 92 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 134 139 134 139 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 144 150 144 150 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
The Effects of Risk Genotypes of the PPARG P12A Polymorphism (PP), the Combination of CAPN10 SNP43/44 (GG/TT), and the Combination of PPARG and CAPN10 SNP43/44 (PP/GG/TT) Together with FPG and BMI for the Risk of Developing T2D
###end title 144
###begin p 145
###xml 0 1 0 1 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 254 255 250 251 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 401 409 397 405 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="st002">Table S2</xref>
###xml 650 651 644 645 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 658 661 652 655 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p &lt;</italic>
###xml 74 86 <span type="species:ncbi:9606">participants</span>
y-Axis denotes incident diabetes estimated as the proportion (percent) of participants who developed diabetes during the follow-up period in the groups with each risk factor defined as risk genotype, elevated FPG (>/=5.6 mmol/l), and high BMI (>/=30 kg/m2). The absolute number of individuals who developed diabetes in the groups with each risk factor is given within the bars (in parentheses) and in Table S2. The incidence of T2D was significantly increased in carriers of the risk PP genotype, GG/TT genotypes, and PP/GG/TT genotypes with elevated FPG and high BMI as compared with individuals carrying low risk genotypes without risk factors (chi2 test, p < 0.001).
###end p 145
###begin title 146
###xml 72 77 72 77 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
The Effect of Insulin Resistance Together with the Risk Genotype of the PPARG P12A Polymorphism on Risk of Developing T2D
###end title 146
###begin p 147
###xml 0 1 0 1 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 34 35 34 35 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 97 99 97 99 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
y-Axis denotes HR and its 95% CI. x-Axis denotes increase in insulin resistance estimated as HOMAIR.
###end p 147
###begin title 148
###xml 32 44 <span type="species:ncbi:9606">Participants</span>
Clinical Characteristics of the Participants at Baseline
###end title 148
###begin title 149
Allele and Genotype Frequencies of the Studied Polymorphisms
###end title 149
###begin title 150
Risk of Developing T2D in Different Genotype Carriers of the Studied Polymorphisms
###end title 150
###begin title 151
Risk of Developing Earlier Onset T2D in Different Genotype Carriers of the Studied Polymorphisms
###end title 151
###begin p 152
Citation: Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, et al. (2005) Genetic prediction of future type 2 diabetes. PLoS Med 2(12): e345.
###end p 152

